Abstract
BACKGROUND: Recent studies have highlighted the vital role of CORO2A in tumor proliferation, migration, and metastasis. However, its immunological and prognostic significance across various cancers remains poorly understood. METHODS: We conducted an analysis of CORO2A expression patterns, prognostic value, and immunological associations across multiple cancers using data from TCGA, Kaplan-Meier Plotter, PrognoScan, TISIDB databases, as well as GEPIA2, TIMER2, and Xiantao Academic Web. Additionally, CORO2A-associated gene enrichment analysis was performed using STRING, GEPIA2, GO, DAVID, and KEGG datasets. RESULTS: Our findings revealed elevated CORO2A expression in most cancers compared to corresponding normal tissues. Lower CORO2A expression was associated with longer OS (overall survival), DFS (disease-free survival), RFS (recurrence-free survival), and DMFS (distant metastasis-free survival) in some cancer types, while the opposite trend was observed in others. CORO2A expression showed significant correlations with the abundance of tumor-infiltrating lymphocytes, immunomodulators, chemokines, as well as the infiltration levels of CAF (cancer-associated fibroblasts) and MDSC (myeloid-derived suppressor cells) across various cancers. We also found that the expression of CORO2A closely related to the markers of immune cell in LUAD and LUSC. Enrichment analysis revealed that CORO2A-related genes were primarily involved in actin filament organization, cell leading edge dynamics, actin binding, and pathways related to pathogenic Escherichia coli infection. CONCLUSION: Our pan-cancer study provided a relatively comprehensive understanding of the oncogenic roles of CORO2A across different tumor types. We identified CORO2A as a prognostic biomarker and demonstrated its correlation with immune cell infiltration in pan-cancer contexts.